EUVIMEDEUVIMED entdecken
Crossref

Near‐Infrared Imaging Agent ABSi‐148 Alleviates CA IX ‐Mediated Hypoxic Fibrosis in Inflammation‐Cancer Transition

Zhi Cao iD, Jingmin Li iD, Weibin Hu iD, Jian Xu iD, Fengyun Zhao iD, Yishu Wang iD, Shuanglin Qin iD, Ming Liu, Ping Wang iD, Jingwei Duan iD, Wensheng Zhou iD, Zhaowei Ding iD und 3 weitere

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202404935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Zhi Cao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Sou…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carbonic Anhydrase IX, Carcinoma, Pancreatic Ductal, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Science and Technology Planning Project of Shenzen Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains a formidable challenge due to its late diagnosis and intrinsic treatment resistance, exacerbates by its development from chronic inflammation to cancer transition (ICT). Here, this investigation aims to develop and evaluate ABSi‐148, a novel near‐infrared (NIR) agent targeting hypoxic carbonic anhydrase IX ( CA IX ), for its potential applications in ICT imaging and even PDAC treatment. ABSi‐148 is synthesized from 4‐(2‐Aminoethyl) benzene sulfonamide (ABS), a sulfonamide derivative, conjugating with MHI‐148 dye with merits of exceptional NIR‐emitting traits, high biocompatibility, and deep tissue penetration imaging capability. It selectively accumulates in CoCl 2 ‐induced pancreatic stellate cells and pancreatic cancer cells via binding with transmembrane CA IX in vitro. Meanwhile, ABSi‐148 effectively visualizes the early pancreatic lesion, and its long‐term administration inhibits the progression of hypoxia‐related fibrosis involved in pancreatic intraepithelial neoplasias (PanINs), and even PDAC progression in vivo. Besides, ABSi‐148 monitors treatment efficacy and localizes hypoxic tumor regions, enhancing survival in tamoxifen combined with caerulein‐induced KPC mice. Overall, ABSi‐148 emerges as a theranostic NIR agent for precise diagnosis and targeted therapy in ICT of PDAC, promising to alleviate tumor progression and enhancing outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarbonic Anhydrase IXCarcinoma, Pancreatic DuctalInflammationSulfonamidesAnimalsMiceHumansCell Line, TumorFibrosisHypoxia

Stichwörter der Autor:innen

carbonic anhydrase IXfibrosisinflammation to cancer transitionnear infrared imagingpancreatic ductal adenocarcinoma

Substanzen

Carbonic Anhydrase IXSulfonamides

Autor:innen und Institutionen

  • Department of Gastroenterology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.
  • Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, China, Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, 510631, China.
  • Department of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
  • Internal medicine department, Guangzhou women and children's Medical Center, Guangzhou, 510623, China.
  • Department of Nuclear Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, 518037, China.
  • Stroke center, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510799, China.

ORCID-Profile: Zhi Cao, Jingmin Li, Weibin Hu, Jian Xu, Fengyun Zhao, Yishu Wang, Shuanglin Qin, Ping Wang, Jingwei Duan, Wensheng Zhou, Zhaowei Ding, Xiaodong Ma, Lisheng Wang

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Science and Technology Planning Project of Shenzen Municipality
  • Guangzhou Municipal Science and Technology Project

Zitieren

APA

Cao, Z., Li, J., Hu, W., Xu, J., Zhao, F., Wang, Y., Qin, S., Liu, M., Wang, P., Duan, J., Zhou, W., Ding, Z., Tang, S., Ma, X., & Wang, L. (2025). Near‐Infrared Imaging Agent ABSi‐148 Alleviates CA IX ‐Mediated Hypoxic Fibrosis in Inflammation‐Cancer Transition. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202404935

Vancouver

Cao Z, Li J, Hu W, Xu J, Zhao F, Wang Y, et al. Near‐Infrared Imaging Agent ABSi‐148 Alleviates CA IX ‐Mediated Hypoxic Fibrosis in Inflammation‐Cancer Transition. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202404935

BibTeX
@article{Cao2025,
  author = {Cao, Zhi and Li, Jingmin and Hu, Weibin and Xu, Jian and Zhao, Fengyun and Wang, Yishu and Qin, Shuanglin and Liu, Ming and Wang, Ping and Duan, Jingwei and Zhou, Wensheng and Ding, Zhaowei and Tang, Shaohui and Ma, Xiaodong and Wang, Lisheng},
  title = {Near‐Infrared Imaging Agent ABSi‐148 Alleviates CA IX ‐Mediated Hypoxic Fibrosis in Inflammation‐Cancer Transition},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202404935}
}
Kostenlos starten →